The prognostic value of adnexal findings in chronic GVHD (cGVHD) has not been investigated in children. Dermatologic examinations were performed in a severe cohort of 11 children with skin cGVHD seen over a 2-year period. Findings were compared with 25 additional patients with skin cGVHD and 97 control patients. In 36 patients with skin cGVHD, nail dystrophy was present in 45% of patients, and was significantly associated with sclerotic disease and lung cGVHD. Pterygium inversum unguis (PIU) was associated with severe lung disease, with significantly lower % predicted FVC and FEV1 in those with PIU than those without. Forty-four percent of GVHD patients had preceding peripheral edema and 56% had preceding peripheral eosinophilia. Peripheral edema and eosinophilia were significantly associated with sclerotic cGVHD and persisted until the diagnosis of cGVHD in all patients. Comparison of data with control patients showed that incidence of nail dystrophy, incidence of peripheral edema and mean peak peripheral eosinophil count of patients with skin cGVHD was significantly higher than those without cGVHD. This study suggests that nail dystrophy, persistent peripheral edema and persistent peripheral eosinophilia are harbingers of severe cGVHD of the skin in children. The presence of PIU may be a harbinger of severe lung involvement.
INTRODUCTION
Chronic GVHD (cGVHD) is a significant cause of morbidity and mortality in children, second only to relapse of disease. [1] [2] [3] Mortality from pediatric cGVHD has been estimated at 41%. 4 However, prognostic indicators for morbidity and mortality secondary to cGVHD have not been clearly identified in children.
The skin is the most commonly affected organ in cGVHD and its involvement may be predictive of a poor prognosis. 5 Chronic skin GVHD may present in multiple different ways ranging from xerosis to erythroderma to sclerotic changes. Adnexal structures may also be involved in cGVHD, resulting in nail dystrophy or alopecia.
Clinically, we have observed that patients with adnexal involvement are less likely to respond to standard therapies. The nail matrix and hair follicle are known to be sites of immune privilege, with decreased HLA-A, B and C expression on keratinocytes and melanocytes as well as decreased MHC class II expression of epidermal antigen presenting cells. [5] [6] [7] Downregulation of antigen recognition and T-cell activation decreases the likelihood of cGVHD at these sites. Thus adnexal involvement may indicate more profound immune dysregulation and predict treatment-refractory disease.
The primary goal of our study was to investigate whether the presence of adnexal involvement in skin cGVHD was associated with severe disease. We also examined the incidence of edema and eosinophilia as potential early signs of skin cGVHD. Finally, we provide a descriptive analysis of a severe cohort of pediatric patients with skin cGVHD.
MATERIALS AND METHODS

Study design
This study was a single-center cross-sectional cohort study of pediatric hematopoietic SCT (HSCT) recipients with a diagnosis of skin cGVHD seen by pediatric dermatologists at Dana-Farber Cancer Institute/Boston Children's Hospital over a 2-year period (February 2011 through March 2013). Retrospective chart review of pediatric HSCT recipients transplanted between 2006 and 2012 was also performed. IRB approval through the Office of Human Research Studies at DFCI was obtained.
For the cross-sectional cohort study, inclusion criteria included age at HSCT ⩽ 18 years, recipient of allogeneic HSCT, and the diagnosis of skin cGVHD. Exclusion criteria included recipient of ⩾ 2 HSCT, and HSCT performed at an outside institution. For the diagnosis of cGVHD, patients either met diagnostic criteria established by the 2005 NIH Consensus Development Project, or had a new onset persistent skin eruption consistent with a feature listed in this report. 8 Informed consent was obtained by the patient and/or legal guardian.
During their dermatology visit, eligible patients were recruited and enrolled in the study, which included a one time evaluation of their skin. Participants had a complete examination of the skin, mucous membranes, hair and nails by at least one of the two dermatologists (authors JTH, AS). All abnormalities were documented and photographed. Patients and their legal guardians completed age-appropriate PedsQL questionnaires. 9 Medical records of participants were reviewed and additional data were gathered, including general demographic data (age, gender), primary disease/reason for HSCT, source of HSCT, conditioning regimen, HLA match, gender of donor, history of acute GVHD (aGVHD), past and current immunosuppressive medications. Laboratory results and relevant radiographic studies were reviewed. When available, lowest pulmonary function test (PFT) data (%predicted FVC and FEV1) were recorded.
Medical records of all pediatric patients who received an unrelated HSCT between May 2006 and August 2012 (date range HSCT was performed in study cohort) were also reviewed. We gathered data on two separate populations: (1) those with a history of skin cGVHD and (2) those without any history of cGVHD (control group). Patients excluded from this analysis included those with ⩾ 2 HSCT (including autologous HSCT), double cord transplants, death due to acute complications, and relapse of primary condition. In patients with skin cGVHD, any documentation of nail dystrophy, eosinophil counts, and peripheral edema around time of cGVHD diagnosis was recorded. In control patients, any documentation of nail dystrophy, eosinophil counts and peripheral edema from 100 days post-HSCT to May 2013 was recorded. In controls, high eosinophil counts attributed to acute GVHD were excluded.
Study aims
The primary aim of our study was to investigate whether adnexal involvement, including nail dystrophy and alopecia, in skin cGVHD was predictive of more severe disease. Secondary aims of our study were to identify early signs of skin cGVHD, and to provide a descriptive analysis of our cohort.
Study definitions
Date of cGVHD was defined as onset of symptoms that were ultimately diagnostic of cGVHD. Determination of overall cGVHD severity was based on the scoring system proposed by 2005 NIH Consensus Development Project. 8 Fully matched patients had no identified mismatches at HLA-A, -B, -C and -DRB1 by high resolution typing if the graft source was BM or no identified mismatches at HLA-A, -B, -DRB1 by intermediate resolution typing if the graft source was cord blood. De novo onset type of cGVHD was defined as no prior history of acGVHD, quiescent onset type of cGVHD was defined as history of aGVHD with absence of immunosuppressive medications at the time of onset of cGVHD, and progressive onset type of cGVHD was defined as history of aGVHD with presence of immunosuppressive medications at the time of onset of cGVHD. 10, 11 Data analysis Characteristics of each group were summarized using descriptive methods. Comparisons of categorical variables, such as peripheral edema, nail dystrophy and PIU, were based on Fisher's exact tests; comparisons of continuous variables, such as peripheral eosinophil counts, were based on two-sample t-tests. Statistical significance was defined as P o0.05. There were no adjustments for multiple comparisons.
RESULTS
Demographics
Eleven pediatric HSCT recipients with skin cGVHD were enrolled in the cross-sectional cohort study (study cohort). These patients were transplanted between May 2006 and August 2012. There were an additional 25 patients with skin cGVHD who were transplanted during this time period, 12 of whom had active skin disease during the study time period of 2011 to 2013. Of these 12 patients, 10 were noted to have eczematous or erythematous skin eruptions, and were not seen by dermatologists during the study period. The remaining two had sclerotic disease; one declined study enrollment, and the other was critically ill and deemed unsuitable for the study.
Between May 2006 and August 2012, there were 209 recipients of unrelated HSCT performed at our institution. Of these 209 patients, 18 had received ⩾ 2 HSCT (including autologous HSCT), 1 had a double cord transplant, 25 died of acute complications, 21 had subsequent relapse of their primary condition and 47 patients had chronic GVHD (36 of whom had skin involvement). The remaining 97 patients were included in our control group.
Demographic data of patients with skin cGVHD and controls are summarized in Supplementary Appendix A. Control patients were significantly younger than cGVHD patients. Otherwise, there were no significant differences in patient demographics.
Characteristics of cGVHD Characteristics of cGVHD in all 36 patients with skin cGVHD are summarized in Table 1 . Overall, 42% (15/36) of patients had sclerotic cGVHD, 69% of patients had skin manifestations upon initial presentation of cGVHD, 69% of patients had extracutaneous involvement, including 39% with involvement of both mucous membranes and visceral organs. Patients with sclerotic cGVHD were significantly more likely than those with nonsclerotic skin involvement to have steroid-resistant disease (13/15 versus 4/21, P = 0.0001). At the time of publication, a significantly higher proportion of patients with sclerotic disease than those with nonsclerotic skin disease had subsequently died of treatment related causes (9/15 versus 4/21, P = 0.02; Table 2 ). Patients in the study cohort were significantly more likely than nonstudy cGVHD patients to have sclerotic cGVHD (8/11, 73% versus 7/25, 28%, P = 0.025). There were no significant differences in extracutaneous organ involvement, steroid responsiveness or death rates between cohorts (Table 1) .
Dermatologic assessment of study cohort Median time from initial development of skin cGVHD to time of study enrollment was 196 days (range 48-1617 days). Eight of 11 patients in the study cohort had sclerotic cGVHD. Of these eight patients, five had lichen sclerosus, dermal fibrosis and myofascial involvement; two had myofascial involvement alone; and one had dermal fibrosis and myofascial involvement. Lichen sclerosus-like changes occurred predominantly at flexural regions. One patient had penile lichen sclerosus et atrophicus (Figure 1 ). The three patients without sclerotic features had eczematous/follicular cGVHD (two) and ichthyosiform cGVHD (one; Figure 2 ). Dyspigmentation (both hyperpigmentation and hypopigmentation) was a prominent feature in all the 11 patients. Vitiliginous changes, including skin depigmentation and poliosis, were noted in four patients with sclerotic cGVHD.
Seven patients had some form of nail dystrophy noted at the study visit. Five patients had nail findings consistent with pterygium inversum unguis (PIU, Figure 3) . The two remaining patients, had longitudinal ridging and splitting of their nails. In all the patients, nail changes predominantly involved fingernails. Eight patients had scalp involvement with scaling of the scalp and/or hair thinning.
Adnexal involvement in skin cGVHD There were 31 patients with documented nail exams (11/11 in study cohort and 20/25 in nonstudy cohort). Of these 31 patients, there were 14 patients with nail dystrophy. The majority of patients with nail dystrophy (9/14) had findings of longitudinal ridging and distal splitting of the fingernails. Specific nail findings are listed in Supplementary Appendix B. Analysis of nail dystrophy was limited to study and nonstudy patients with documented nail exams.
Patients with nail dystrophy were significantly more likely than those with normal nails to have sclerotic disease (11/14 versus 3/17, P = 0.001). Patients with nail dystrophy were also more likely to have steroid-resistant disease and lung cGVHD (11/14 versus 3/17, P = 0.001, and 8/14 versus 2/17, P = 0.02, respectively). Twenty-three of the 31 patients with documented nail exams had PFTs performed at our institution. Analysis of PFT results revealed that patients with nail dystrophy had significantly lower % predicted FVC and FEV1 than those without nail dystrophy (Table 3) .
Within the study cohort, patients with PIU were significantly more likely than those without PIU to have lung cGVHD (5/5 versus 0/6, P = 0.002, Table 3 ). All five patients with PIU had evidence of significant lung cGVHD. Analysis of PFT results revealed that patients with PIU had significantly lower % predicted FVC than those without PIU (20.4 versus 85%, P o0.0001). Similarly, patients with PIU had significantly lower % predicted FEV1 than those without PIU (14.6 versus 85%, Po 0.0001). Of the five patients with PIU, four were referred for lung transplant evaluation and the remaining patient was screened and not considered a candidate due to her severe multisystem disease. Lung biopsy results of four patients with PIU were reviewed, showing varying degrees of cGVHD. PIU was also significantly associated with a lower quality of life based on self report using the PedsQL questionnaire (PedsQL score 51.4 versus 69.3, P = 0.009). Due to lack of detailed documentation of nail findings in nonstudy patients, analysis of PIU was limited to study patients.
There was sufficient documentation of nail findings in only five patients to inform a temporal relationship between nail dystrophy and cGVHD. Three of these patients had nail dystrophy occurring 0, 3 and 5 months before sclerotic disease and two patients had nail dystrophy occurring 2 months and 5 years before the onset of severe lung cGVHD. Of note, four of five study patients with PIU had no prior documented nail exam. Medical record review identified three patients transplanted between 2006 and 2012 who developed lung cGVHD without skin involvement. Notably, all the three patients had normal nail exams.
Control group. Of the 97 control patients, no nail exam was documented in 29, normal nails were documented in 63 and dystrophic nails were documented in 5 patients. Of the five patients with nail dystrophy, two had a primary diagnosis of dyskeratosis congenita, and one had a primary diagnosis of Fanconi anemia, all with nail abnormalities before HSCT. Of the remaining two patients, one had documentation of 'distal nail dystrophy' at a single visit that had resolved by the following visit, and one had documentation of thickened and discolored great toenails. The incidence of nail dystrophy in cGVHD patients was significantly higher than that of the control group (Table 4) .
Peripheral edema in skin cGVHD A total of 16 patients (6 in the study cohort; 10 in the nonstudy cohort) were noted to have otherwise unexplained edema of the lower ± upper limbs before the onset of skin cGVHD. One study patient also had scrotal edema (Figure 4) . Thirteen of 16 patients subsequently developed sclerotic cGVHD with mean time from onset of edema to evident sclerotic disease of 58.5 days (range 10-243). The patient with scrotal edema developed lichen sclerosus of the glans penis. All 13 patients were noted to have sclerotic changes immediately upon resolution of edema. Of note, the remaining two patients with sclerotic disease who did not have preceding edema were on prednisone at time of cGVHD onset. Patients with sclerotic cGVHD were significantly more likely to have peripheral edema than patients with nonsclerotic disease (Table 2) .
Control group. Of the 97 patients in our control population, peripheral edema was documented in 8 patients. Causes of peripheral edema were identified in four of eight patients; two with arthritis and two with renal disease. The remaining four patients had self resolution of edema within 2 weeks, without intervention. There was a significantly higher incidence of peripheral edema in skin cGVHD patients compared with our control group (Table 4) .
Peripheral eosinophilia in skin cGVHD Thirty-four cGVHD patients (11 in study cohort; 23 in nonstudy cohort) had documented eosinophil counts within 2 months before the diagnosis. Mean peak peripheral eosinophil count was 1140 cells/μL (s.d. 1160). There was no significant difference in mean peak peripheral eosinophil count in patients with sclerotic disease than in those with nonsclerotic disease. However, patients with sclerotic cGVHD were significantly more likely to have peripheral eosinophilia (eosinophil count 4500 cells/μL) than patients with nonsclerotic disease (12/14 versus 7/20, P = 0.005; Table 2 ). Medical record review revealed no other identifiable causes of eosinophilia.
In the subset of patients with eosinophilia (n = 19), the mean time from the onset of eosinophilia to symptoms of cGVHD was 54 days (range 0-182 days). Eosinophilia persisted until diagnosis and treatment of cGVHD in all 19 patients.
Control group. Thirty-two patients of the control group had peripheral eosinophilia (4500 cells/μL) at some point during this time period. Of these 32 patients, 66% (21/32) had resolution of eosinophilia within 1 month or by the following visit. Cause of eosinophilia was identified in 20 patients, with most common causes being eczema and infection.
The mean peak peripheral eosinophil count and incidence of eosinophilia was significantly higher in our cGVHD patients than in our controls (Table 4) . DISCUSSION Nail dystrophy has been described in the literature as a manifestation of cGVHD. 8 Many forms of nail dystrophy are a Figure 3 . Pterygium inversum unguis in four patients with severe cGVHD characterized by sclerotic involvement and lung disease. Abbreviations: PFT = pulmonary function test; PIU = pterygium inversum unguis. a No PFT data on eight patients in entire skin cGVHD cohort, one patient in study cohort.
b Analysis based on total of 31 study and nonstudy cGVHD patients with documentation of nail dystrophy. c Analysis based on 11 cGVHD study patients.
result of injury or inflammation of the nail matrix. Disturbances of the nail matrix, ordinarily a site of immune privilege, in GVHD may be an indication of severe immunologic dysfunction. However, there has been no prior investigation of nail involvement as an indicator of prognosis.
In our study, nail dystrophy was present in more than half of patients with skin cGVHD, the majority of whom had findings of longitudinal ridging, splitting and PIU. Our study demonstrated nail dystrophy to be significantly associated with sclerotic disease as well as lung cGVHD. In five patients with adequate documentation, nail dystrophy was present before the symptoms of cGVHD. Comparison of our findings with control patients showed that nail dystrophy was uncommon in HSCT recipients at our institution overall, and suggested that nail dystrophy may be a significant and specific finding in this population.
Within our study cohort of 11 patients, PIU was present in all 5 patients with lung cGVHD, and was significantly associated with poor pulmonary function. PIU is a specific form of nail dystrophy that is characterized by adherence of the distal portion of the nailbed to the ventral surface of the nail plate. PIU has been rarely reported as a manifestation of cGVHD. 12, 13 Interestingly, PIU has also been described as a characteristic nail finding in patients with systemic scleroderma, but not in those with limited skin involvement (localized morphea).
14 An association between PIU and lung cGVHD has not been previously reported and the pathogenesis of this association is unknown.
Thirty percent of control patients, and 14% of cGVHD patients had no documented nail exams in their medical record. Four of five patients with PIU in the study cohort had no prior documentation of nail dystrophy, suggesting that the nail exam may often be overlooked. Given our nail findings, we recommend careful evaluation of adnexal structures in HSCT recipients, paying close attention to those with cGVHD. In patients with nail dystrophy, particularly with findings of PIU, we suggest close monitoring of PFTs to assess for lung cGVHD.
Peripheral edema as an early sign of sclerotic cGVHD has been previously reported. [15] [16] [17] [18] Recently, it has been postulated that edema associated with cGVHD may be due to endothelial activation and injury. 18 In our study, peripheral edema was a preceding sign in 13 of 15 patients with sclerotic cGVHD with a mean time of onset of 58.5 days before the development of sclerotic disease. In these patients, peripheral edema persisted until sclerotic features became evident. Medical record review of control patients showed that peripheral edema was not only significantly less common in those without cGVHD, but also more likely to self-resolve in cases without identifiable cause. Although other causes should be considered in these medically complex patients, persistent peripheral edema in the post-HSCT recipient should be evaluated with particular concern for sclerotic cGVHD.
Peripheral eosinophilia has also been described as a preceding sign of cGVHD, but not a predictor of outcome, in both adults and children. 10, 19, 20 In our study, patients with skin cGVHD had a significantly higher mean peak peripheral eosinophil count than control patients, with a mean time of onset of eosinophilia of 54 days before the symptoms of cGVHD. Patients with sclerotic cGVHD were more likely to have preceding eosinophilia than those with nonsclerotic disease. Although all cGVHD patients with eosinophilia had persistently elevated eosinophil counts to the time of diagnosis of cGVHD, 66% of control patients had resolution of eosinophilia at the following visit or blood draw. Our results corroborate previous data supporting peripheral eosinophilia as an early marker for cGVHD, and suggest persistence of eosinophilia to be a more specific sign.
Finally, sclerotic cGVHD in adults has been associated with the need for prolonged immunosuppression, significant functional impairment and, more variably, decreased survival. 14, 15 In our study, patients with sclerotic disease also had worse outcomes, with a significantly increased incidence of steroid-resistant disease and higher death rate. Patients with sclerotic disease were also more likely to have nail dystrophy, preceding peripheral edema and preceding eosinophilia than those with nonsclerotic disease. Although the temporal relationship between nail dystrophy and disease onset needs to be defined, our data suggests that these physical exams and laboratory findings may be harbingers of severe skin cGVHD in children.
Given the rarity of chronic GVHD in the pediatric population, our study was limited by small study size. In addition, our study cohort represented a severe subset of children with chronic GVHD, skewed largely by referral bias of treatment resistant patients to dermatology. Thus, we incorporated retrospective data on cGVHD patients who were not enrolled in our study whenever possible to further substantiate our findings. However, we were not able to use retrospective data to evaluate associations with PIU due to limited available documentation. Finally, the cross-sectional nature of our study limited our ability to establish a clear timeline of events with regards to adnexal involvement and disease outcome. Future longitudinal studies with pre-and post transplant assessments should be useful in investigating the predictive value of our findings.
This study investigated a group of pediatric skin cGVHD patients at a single institution, and identified several cutaneous and non-cutaneous features were associated with severe disease. Our data suggest that nail dystrophy, persistent peripheral edema and persistent peripheral eosinophilia are harbingers of severe cGVHD of the skin in children. In addition, the presence of PIU may be a harbinger of severe lung involvement in cGVHD. Larger prospective studies are indicated to confirm our findings.
